Dou L, Meng D, DongY, et al. - As sepsis patients often exhibit significant alterations in pharmacokinetics characteristics of linezolid, researchers sought to determine target pharmacokinetics/pharmacodynamics (PK/PD) index of the efficacy of linezolid treatment, and to identify the optimum dosage regimen of linezolid in sepsis patients. They modeled the PK data using one compartment model and ascertained the target PK/PD index for successful treatment by logistic regression. Observations revealed that for sepsis patients treated with linezolid, there was requirement for an AUC₂₄/MIC of 100 to achieve a bacterial eradication rate of 80%. They identified 800 mg every 12 h (safety probability 66.8%) dosing regimen as suitable for sepsis patients with normal renal function or kidney damage with mildly. Given the high incidence of thrombocytopenia in sepsis patients on CRRT, they emphasize undertaking therapeutic drug monitoring for optimizing linezolid exposure in sepsis patients.